THE ANUP ENGINEERING LTD · QQ1 FY-2027 · THE CALL

Severe margin collapse masks recovery hopes—FY26 guidance massively missed

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q1 FY27 results ANUPThe Anup Engineering Ltd19 Aug 2026 · 6 min read

Verdict

Sell

confidence 8/10

Credibility

Grade D

FY26 guidance (15-20% growth, 22% EBITDA margin, 50%+ exports) withdrawn by massive misses; Q1 shows no tangible recovery—pipeline unproven.

Short-term outlook

Negative

next 1–2 quarters

Long-term outlook

Cautiously Optimistic

multi-year

Anup missed all FY26 guidance by massive margins: revenue -28.5% YoY (not +15-20%), NPM 0.5% (not 22% EBITDA), exports in retreat (not >50%). Management offers vague recovery linked to a ₹1.1k Cr inquiry pipeline with no firm orders, conversion risk, or timeline. Q1 shows zero margin expansion—OPM 7.6%, NPM 0.5%—contradicting claims of structural improvement. The key risk: order pipeline may not materialize, exports may remain weak, working capital stress may persist. Confidence in guidance restored only when firm orders materialize and margins begin to recover.

₹125.2 Cr

Revenue · −28.5% YoY

₹0.6 Cr

Reported PAT · −97.8% YoY

Compressing

Margins · vs guidance: Overstated

Did the claims hold up?

Management's claims vs. the numbers

₹1,100 Cr inquiry pipeline supports recovery

OVERSTATED

Revenue -28.5% YoY to ₹125.2 Cr; inquiry vs order conversion unclear; no near-term revenue visibility

Exports exceed 50% (prior guidance)

MISS

Transcript does not quantify export %; export stress evident from decline. Prior target not met.

EBITDA margin around 22% (FY26 guidance)

MISS

NPM compressed to 0.5%; OPM 7.6%. Q1 utter margin collapse vs 22% target.

Improved working capital management planned

Partial

Working capital stress cited; no metrics or timeline given. Defensive tone on execution.

Earnings quality

What changed since the last call

Deltas vs. the prior call

FY26 revenue growth guidance

Withdrawn

Prior: 15-20% growth guidance; Q1 showed -28.5% YoY. Guidance implicitly cut by massive miss; no revised FY27 target stated.

EBITDA margin target

Withdrawn

Prior: ~22% EBITDA margin; Q1 NPM 0.5%, OPM 7.6%. No revised margin target; recovery vague and unquantified.

Export % contribution

Downgrade

Prior: >50% exports; Q1 shows export stress. Management silent on export %; no recovery credibility.

The Q&A

Analysts pressed hard on margins, working capital, and order pipeline conversion. Management acknowledged stress but offered only vague recovery plans, no timelines, no metrics. Tone defensive—management did not hold ground on guidance credibility.

The exchanges that mattered

Margin recovery timing — Unnamed analyst

Partial

Management cited cost reduction initiatives and pricing adjustments underway by H2 FY27; no specific margin target or % recovery path provided.

Order pipeline conversion — Unnamed analyst

Dodged

Pipeline is robust and we are confident; specifics on conversion rate, timeline, or firm order status withheld.

Working capital cycle — Unnamed analyst

Dodged

Working capital under management; improvement initiatives underway; no actual metrics (DSO, DIO, days payable) disclosed.

Export revenue recovery — Unnamed analyst

Dodged

Export business is being revived; prior guidance >50% reiterated without current % or timeline.

Guidance

Forward guidance and management's confidence

Prior FY26: 15-20% growth; Q1 -28.5% YoY (guidance missed)

Low

Guidance implicitly withdrawn by massive miss. FY27 revenue target not stated.

Recovery by H2 FY27 (vague, no number)

Low

Management confident on ₹1.1k Cr pipeline; no conversion %, firm order count, or revenue contribution quantified.

Prior FY26: ~22% EBITDA margin; Q1 delivered OPM 7.6%, NPM 0.5%

Low

Margin target implicitly cut. No revised FY27 margin target. Recovery plan: cost reduction & pricing (unquantified).

Risks the call surfaced

Ranked by how much they should concern a holder

Order pipeline conversion

High

₹1.1k Cr inquiry pipeline is pre-order stage. Conversion rate, timeline, and firm order status undisclosed. If pipeline stalls, no revenue recovery.

Export revenue decline

High

Prior guidance: exports >50% of revenue. Q1 shows export stress; % not disclosed. If exports do not recover, revenue base permanently lower.

Margin compression unresolved

High

Q1 NPM 0.5%, OPM 7.6% vs ₹22% EBITDA prior guidance. Cost inflation, pricing pressure, or mix deterioration evident. Recovery plan vague (cost reduction, pricing); no timeline or credibility.

Working capital stress

Medium

Management cites working capital deterioration; no turnover metrics, days of payable outstanding, or recovery timeline provided. If not resolved, cash flow squeeze risk.

Management credibility erosion

High

FY26 guidance (15-20% growth, 22% EBITDA, 50%+ exports) missed by massive margins. Recovery claims lack execution proof; Q1 shows no tangible progress. Investor trust in forward guidance at historical lows.

Management

Score 4/10. Defensive & evasive. Management acknowledged margin collapse & working capital stress but withheld metrics (DSO, DIO, export %, conversion rates). Vague on recovery timeline. Poor. Missed FY26 guidance on all key metrics: revenue -28.5% vs +15-20%, EBITDA margin 7.6% OPM vs ~22%, exports in retreat. Q1 shows no recovery execution.

What to watch next

1 · Q2-Q3 FY27
Inquiry pipeline conversion to firm orders; export revenue stabilization
2 · H2 FY27
Margin recovery initiative results—cost reduction, pricing power, or product mix improvement
3 · Ongoing
U.S.-India trade deal resolution impact (prior mention); order book visibility

Confidence in guidance restored only when firm orders materialize and margins begin to recover.

Informational and educational content only. Not investment advice.